These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 4055987)

  • 1. Pharmacokinetics of melatonin in man: first pass hepatic metabolism.
    Lane EA; Moss HB
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1214-6. PubMed ID: 4055987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications.
    Yeleswaram K; McLaughlin LG; Knipe JO; Schabdach D
    J Pineal Res; 1997 Jan; 22(1):45-51. PubMed ID: 9062870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol.
    Yoon IS; Choi MK; Kim JS; Shim CK; Chung SJ; Kim DD
    Xenobiotica; 2011 Mar; 41(3):243-51. PubMed ID: 21128757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
    Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
    Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow.
    Nosadini R; Avogaro A; Mollo F; Marescotti C; Tiengo A; Duner E; Merkel C; Gatta A; Zuin R; de Kreutzenberg S
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1125-32. PubMed ID: 6373811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
    Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.
    Pentikainen PJ; Neuvonen PJ; Tarpila S; Syvälahti E
    Br Med J; 1978 Sep; 2(6141):861-3. PubMed ID: 709096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cimetidine clearance and bioavailability in hepatic cirrhosis.
    Sonne J; Poulsen HE; Døssing M; Larsen NE; Andreasen PB
    Clin Pharmacol Ther; 1981 Feb; 29(2):191-7. PubMed ID: 7460483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
    Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
    Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
    Neal EA; Meffin PJ; Gregory PB; Blaschke TF
    Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatic transport of bilirubin in normal and cirrhotic patients. Compartmental analysis of plasma bilirubin disappearance curves following intravenous overloading].
    Pirotte J
    Biol Gastroenterol (Paris); 1973; 6(3):183-96. PubMed ID: 4792579
    [No Abstract]   [Full Text] [Related]  

  • 18. On the pharmacokinetics of phenacetin in man.
    Raaflaub J; Dubach UC
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):261-5. PubMed ID: 1233222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.
    Huet PM; Lelorier J
    Clin Pharmacol Ther; 1980 Aug; 28(2):208-15. PubMed ID: 7398188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.
    Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O
    Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.